Loading the state's markets…
Loading the state's markets…
Loading the market…
Medicare market size, surgeons and outlook to 2030
Medicare fee-for-service bronchoscopy & lung nodule cases in Mississippi: reported (2020, the pandemic year, left out of the line), then forecast with its 80% range. One year ahead, this procedure’s market forecast has been off by 6% on average (216 state-years, 2020–2024): a close guide.
| Year | Surgeons | Medicare FFS | Advantage share |
|---|---|---|---|
| 2019 | 27 | 1,171 | 22% |
| 2020 | 18 | 876 | 25% |
| 2021 | 20 |
EBUS, navigational and robotic bronchoscopy, endobronchial valves, VATS lobectomy. Professional codes (what the surgeon bills): CPT 31652, 31653, 31628, 31647, 32663.
Surgeons and fee-for-service cases are from CMS’s Medicare Physician & Other Practitioners files, counted where the surgeon billed; state totals include the cases CMS leaves out of the surgeon-level file (under 11 patients). All Medicare adds patients in Medicare Advantage at the state’s enrollment share; all payers scales Medicare by its share of the procedure nationally. The forecast carries cases per resident 65+ forward with the Census projection of residents 65+. How the numbers are made · Data sources
The 10 busiest do 74% of the cases CMS names in Mississippi; 12 surgeons do 80% of them.
MedaRep names every one, ranked by volume, with their practice, hospitals, trend, forecast and which device companies already engage with them.
| Surgeons | Medicare FFS | Growth since 2019 | Per 1,000 | Out of hospital | Forecast | |
|---|---|---|---|---|---|---|
| Colonoscopy & upper endoscopy | 126 | 39,544−7.4%/yr | −7.4%/yr | 108.90.9× | 60% | 37,000 in 2030−1.1%/yr |
| ERCP & endoscopic ultrasound |
Bronchoscopy & lung nodule in every state, and its device makers · Every procedure market in Mississippi · Every state · Compare with Florida
| 2024 |
| 1,240 |
| 46% |
| 2025 est. | ≈ 1,220 | – |
| 2026 est. | ≈ 1,280 | – |
| 957 |
| 32% |
| 2022 | 18 | 953 | 37% |
| 2023 | 19 | 1,063 | 42% |
| 2024 | 20 | 1,240 | 46% |
| 2025 from claims | – | 1,223 1,122–1,294 | 47% |
| 2026 forecast | – | 1,278 1,124–1,475 | 48% |
| 2027 forecast | – | 1,334 1,140–1,590 | 49% |
| 2028 forecast | – | 1,392 1,162–1,705 | 50% |
| 2029 forecast | – | 1,452 1,186–1,821 | 51% |
| 2030 forecast | – | 1,514 1,213–1,940 | 52% |
In 2025, 12% inpatient hospital, 88% hospital outpatient.
| Forecast, Medicare FFS | Inpatient | Hospital outpatient |
|---|---|---|
| 2026 · ~1,300 | ~150 | ~1,100 |
| 2027 · ~1,300 | ~150 | ~1,200 |
| 2028 · ~1,400 | ~150 | ~1,200 |
The forecast’s cases at the projected mix.
If the trend since 2022 holds, slowing as it goes, by 2028: inpatient hospital about 11% (12% in 2025), hospital outpatient about 89% (88% in 2025).
| +1.9%/yr |
| 2.9 |
| 0% |
| 9,990 in 2030+8.7%/yr |
| Tennessee | 58 | 3,989+4.5%/yr | +4.5%/yr | 5.7 | 2% | 5,930 in 2030+6.8%/yr |
| North Carolina | 56 | 3,414+0.2%/yr | +0.2%/yr | 3.5 | 0% | 4,080 in 2030+3%/yr |
| Georgia | 43 | 2,875+5.7%/yr | +5.7%/yr | 3.4 | 0% | 5,590 in 2030+12%/yr |
| Virginia | 42 | 2,548+1.9%/yr | +1.9%/yr | 2.5 | 0% | 4,620 in 2030+10%/yr |
| Maryland | 33 | 2,509+4.4%/yr | +4.4%/yr | 2.9 | 1% | 3,560 in 2030+6%/yr |
| Kentucky | 40 | 2,343+2.3%/yr | +2.3%/yr | 5.2 | 0% | 4,370 in 2030+11%/yr |
| South Carolina | 29 | 1,874+3.7%/yr | +3.7%/yr | 2.8 | 0% | 3,150 in 2030+9%/yr |
| Louisiana | 18 | 1,193+5.7%/yr | +5.7%/yr | 3.0 | 0% | 2,510 in 2030+13%/yr |
| Arkansas | 16 | 1,036−1.8%/yr | −1.8%/yr | 2.8 | 0% | 1,540 in 2030+6.9%/yr |
| Alabama | 19 | 1,031+1.9%/yr | +1.9%/yr | 2.4 | 0% | 1,640 in 2030+8%/yr |
| Oklahoma | 14 | 974+2.6%/yr | +2.6%/yr | 2.0 | 0% | 2,260 in 2030+15%/yr |
| Delaware | 12 | 798+6.5%/yr | +6.5%/yr | 4.7 | 0% | 1,560 in 2030+12%/yr |
| District of Columbia | 7 | 762+4.4%/yr | +4.4%/yr | 12.2 | 0% | 1,250 in 2030+8.6%/yr |
| West Virginia | 4 | 478−5.3%/yr | −5.3%/yr | 2.3 | 0% | 670 in 2030+5.8%/yr |
| 11 |
| 634−4%/yr |
| −4%/yr |
| 1.70.5× |
| 5% |
| 710 in 2030+1.9%/yr |
Share of the cases CMS names by surgeon, by where they billed. Open one for its ranking.
Capsovision leads with 90% of company spending on these surgeons in 2025, level with 2024.
In 2025, 14 companies reported engagement with Mississippi’s surgeons worth $184K in consulting, speaking, meals and travel tied to these products, about $9,207 per surgeon billing it. Royalties are left out.
FDA, last 12 months: 11 clearances and approvals in the category, 4 recalled product lines. A recall is a public FDA notice, not a finding of fault.
Which surgeons each company engages, and the dollars reported, are in the ranking. Open Payments shows the payments companies reported. It suggests engagement, not which devices a surgeon uses, and is not evidence of wrongdoing. Every company in the category.